Last reviewed · How we verify

Secondary glaucoma — Treatment Landscape & Competitive Intelligence

Secondary glaucoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary glaucoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Neptazane METHAZOLAMIDE Pfizer methazolamide Carbonic anhydrase 3 1959-01-01
Diamox ACETAZOLAMIDE Teva Carbonic Anhydrase Inhibitor [EPC] Carbonic anhydrase 1953-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Secondary glaucoma
  2. Pfizer · 1 drug in Secondary glaucoma
  3. Teva · 1 drug in Secondary glaucoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary glaucoma:

Cite this brief

Drug Landscape (2026). Secondary glaucoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-glaucoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing